Gemina Laboratories Income Statement

Financials in millions CAD. Fiscal year is February - January.

Millions CAD. Fiscal year is Feb - Jan.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct '24 Oct 31, 2024	Jan '24 Jan 31, 2024	Jan '23 Jan 31, 2023	Jan '22 Jan 31, 2022	Jan '21 Jan 31, 2021
Selling, General & Admin	2.03	2.61	1.8	1.99	0.18
Research & Development	1.52	2.59	4.15	2.71	0.49
Operating Expenses	3.55	5.2	5.98	4.73	0.67
Operating Income	-3.55	-5.2	-5.98	-4.73	-0.67
Interest Expense	-	-0.02	-	-0	-0
Other Non Operating Income (Expenses)	-	-	0	-	-
EBT Excluding Unusual Items	-3.4	-5.22	-5.98	-4.73	-0.67
Other Unusual Items	-0.02	-	-	-	-0.44
Pretax Income	-3.41	-5.22	-5.98	-4.73	-1.11
Net Income	-3.41	-5.22	-5.98	-4.73	-1.11
Net Income to Common	-3.41	-5.22	-5.98	-4.73	-1.11
Shares Outstanding (Basic)	74	72	60	48	34
Shares Outstanding (Diluted)	74	72	60	48	34
Shares Change (YoY)	6.20%	20.37%	26.30%	41.35%	-
EPS (Basic)	-0.05	-0.07	-0.10	-0.10	-0.03
EPS (Diluted)	-0.05	-0.07	-0.10	-0.10	-0.03
Free Cash Flow	-1.24	-3.29	-4.59	-3.88	-0.43
Free Cash Flow Per Share	-0.02	-0.04	-0.08	-0.08	-0.01
EBITDA	-3.54	-5.18	-5.97	-4.72	-
D&A For EBITDA	0.02	0.02	0.01	0.01	-
EBIT	-3.55	-5.2	-5.98	-4.73	-0.67

Source: S&P Global Market Intelligence. Standard template. Financial Sources.